Sino Biological, Inc., a major biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, has forged a notable partnership with Rapid Novor, Inc, headquartered in Toronto, Canada. This collaboration entails Sino Biological promoting Rapid Novor’s exclusive de novo REmAb monoclonal antibody (mAb) sequencing service alongside its own custom mAb development and production services. The agreement spans across several regions, including China, Singapore, Thailand, Malaysia, Indonesia, Vietnam, Philippines, Japan, and South Korea.

Headquartered in Beijing, China, Sino Biological holds a prominent position in the global biotechnology landscape, specializing in biological research reagents and related technical contract research services. A significant portion of its portfolio revolves around designing, developing, and manufacturing custom monoclonal antibodies for basic research and in vitro diagnostics. By integrating monoclonal antibody sequence data with the delivery of purified, bioactive antibodies, Sino Biological aims to provide clients with invaluable insights into antibody structure and function. This collaboration empowers clients to optimize antibody engineering strategies, safeguard intellectual property, develop new diagnostic platforms, and enhance drug discovery efforts.

Dr. Rob Burgess, Chief Business Officer at Sino Biological, expressed optimism about the partnership, highlighting the synergies between Rapid Novor’s REmAb monoclonal antibody sequencing capabilities and Sino Biological’s antibody development and manufacturing services. “We believe the combination of these services enhances the value of our custom monoclonal antibody products for our clients,” Dr. Burgess stated.

Iain Rogers, VP Commercial at Rapid Novor, emphasized the importance of an integrated solution that provides reliable protein sequencing and recombinant expression. “We are pleased that Sino Biological’s clients will now have access to accurate sequencing through our REmAb technology,” Rogers remarked.

This collaboration signifies a significant advancement in the field of antibody development and underscores the commitment of both companies to delivering cutting-edge solutions to researchers and biotechnology firms across Asia and beyond.

 

Source: globenewswire.com

Report Abuse